The following statement was issued this afternoon by PCPC3 — the patient-centered prostate cancer collaborative coalition: … READ MORE …
Filed under: Diagnosis, Risk | Tagged: coverage, PSA, test | 2 Comments »
New guidance in England has expanded coverage of treatment with abiraterone acetate (Zytiga) + prednisone for men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, coverage, NICE, Zytiga | Leave a comment »
According to an article this morning on the PharmaTimes web site, Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, coverage, enzalutamide, NICE, UK, Xtandi, Zytiga | 3 Comments »
It appears as though, here in the USA, the House of Representatives has decided to block coverage of vacuum erectile devices (VEDs, sometimes known as “penis pumps”) for Medicare patients. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: coverage, device, erectile, Medicare, vacuum, VED | 7 Comments »
An article originally published in Prostate Cancer and Prostatic Diseases, earlier this year, predicts that expansion of insurance coverage here in the USA will have major impact on prostate cancer outcomes in the relatively near future. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: coverage, Diagnosis, insurance, outcome, Treatment | Leave a comment »
The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: coverage, enzalutamide, NICE, UK | 7 Comments »
As one might expect, there is an extremely diverse (and conflicting) range of reactions to the USPSTF recommendation that routine PSA testing of uninformed men is not supported by good evidence and should no longer be considered as appropriate “standard” practice unless there has been a prior discussion of the risks and benefits of the test between patient and doctor. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: benefit, cost, coverage, PSA, risk, USPSTF | 6 Comments »
As many in the prostate cancer community will be aware, there has been a major battle ongoing over whether the drug bevacizumab (Avastin) should continue to be approved by the U.S. Food & Drug Administration (FDA) for the treatment of women with metastatic breast cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Centers for Medicare and Medicaid Services, CMS, coverage, off-label | Leave a comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) — improves health outcomes for Medicare beneficiaries … READ MORE …
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a comment »
Physicians and researchers on a panel advising the Centers for Medicare & Medicaid Services (CMS) gave Provenge® a favorable vote at a “National Coverage Analysis” hearing yesterday in Washington, DC. You could almost hear the world of prostate cancer survivors, their physicians, Dendreon investors, and other drug development companies breathe a sigh of relief! … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: coverage, Medicare, Provenge, sipuleucel-T | 2 Comments »
Yesterday evening, the Centers for Medicare and Medicaid Services (CMS) announced that it was opening a “national coverage analysis to determine whether or not autologous cellular immunotherapy [for prostate cancer with sipuleucel-T/Provenge] is reasonable and necessary.” … READ MORE …
Filed under: Management | Tagged: coverage, Medicaid, Medicare, Provenge, sipuleucel-T | 3 Comments »
Reuters has published a summary report on the discussions of a Medicare advisory panel (MedCAC) held yesterday to address the value of different types of radiation therapy in the treatment of early-stage prostate cancer. … READ MORE …
Filed under: Management | Tagged: coverage, CyberKnife, Medicare, radiation | Leave a comment »
Many readers will be interested in the article titled “Debate surrounds new prostate-cancer treatment” that appeared today in the Philadelphia Inquirer on the topic of prostate cancer treatment costs. … READ MORE …
Filed under: Management, Treatment | Tagged: coverage, CyberKnife, radiotherapy | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 